Published in final edited form as:

Best Pract Res Clin Anaesthesiol. 2013 December ; 27(4): 409–425. doi:10.1016/j.bpa.2013.10.008.

Lymphovascular and neural regulation of metastasis: Shared tumour signalling pathways and novel therapeutic approaches

C.P. Le¹, T. Karnezis^{2,3}, M. G. Achen^{2,3,4}, S.A. Stacker^{2,3,4,*}, and E.K. Sloan^{1,5,6,*}

¹Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria 3052, Australia

²Tumour Angiogenesis Program, Peter MacCallum Cancer Centre, East Melbourne, Victoria 3002, Australia

³Sir Peter MacCallum Department of Oncology, University of Melbourne, Victoria 3010, Australia

⁴Department of Surgery, Royal Melbourne Hospital, University of Melbourne, Parkville, Victoria 3050, Australia

⁵Department of Cancer Anaesthesia and Pain Medicine, Peter MacCallum Cancer Centre, East Melbourne, Victoria 3002, Australia

⁶Cousins Center for PNI, Semel Institute for Neuroscience and Human Behavior, UCLA AIDS Institute and Jonsson Comprehensive Cancer Center, University of California Los Angeles, USA

Abstract

The progression of cancer is supported by a wide variety of non-neoplastic cell types which make up the tumour stroma, including immune cells, endothelial cells, cancer-associated fibroblasts and nerve fibres. These host cells contribute molecular signals that enhance primary tumour growth and provide physical avenues for metastatic dissemination. This article provides an overview of the role of blood vessels, lymphatic vessels and nerve fibres in the tumour microenvironment, and highlights the interconnected molecular signalling pathways that control their development and activation in cancer. Further the review highlights the known pharmacological agents which target these pathways and discusses the potential therapeutic uses of drugs that target angiogenesis, lymphangiogenesis and stress response pathways in the different stages of cancer care.

Keywords

angiogenesis; lymphangiogenesis; beta-blocker; NSAID; vasculature; sympathetic nervous system; SNS; nerve fibres

© 2014 Published by Elsevier Ltd

* Address correspondence to Erica Sloan (erica.sloan@monash.edu) or Steven Stacker (steven.stacker@petermac.org).

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

CONFLICT OF INTEREST

S.A.S. and M.G.A. are shareholders in Circadian Technologies Ltd., a company developing anti-cancer therapeutics.

1. The Tumour Microenvironment Influences Cancer Progression

The initiation and progression of cancer occurs in a microenvironment that consists of a broad range of non-neoplastic cells that make up the tumour stroma [1, 2]. The stroma comprises extracellular matrix, endothelial cells and pericytes, fibroblasts, mesenchymal stem cells, neural cells and immune cells including natural killer cells, macrophages and dendritic cells. The stroma connects to the broader circulatory system of blood and lymphatic vessels, and has receptors that make stromal cells responsive to signals from the peripheral autonomic nervous system (Figure 1). In the peripheral tissues and within the tumour stroma, blood and lymphatic vessels exchange fluid and cells via specialised small capillaries while nerve fibres exchange molecular information via specialised synapses with other cell types. Together this collection of cells and matrix is the source of many important molecular signals that help to either promote or retard cancer growth and dissemination [3, 4].

Prior to the initiation of cancer, normal human tissue is a highly ordered series of specialised cell types that function for a common purpose. Endothelial cells and nerve fibres share receptors for guidance cues that direct their growth and maturation [5]. During embryonic development, activation of these receptors results in common patterns of migratory behaviour by nerve fibres and blood vessels to support limb and muscle development [5]. In the adult this results in co-localization of nerve fibres, blood vessels and lymphatic vessels in neurovascular bundles. While related in their migratory passage into tissue, these three structures carry out diverse functions relating to tissue homeostasis. Blood vessels are part of the high pressure cardiovascular system that carries cells, protein-rich fluid and macromolecules to tissues. Arterial blood vessels connect to capillary beds where nutrients and waste products are exchanged from cells, and blood is then returned to the heart via veins. The function of the blood vasculature is complemented by lymphatic vessels that return cells and fluid from the interstitium back to the blood circulation [6]. Lymphatics start as small blind-ended vessels in the periphery which are known as initial lymphatics. The initial lymphatic vessels within tissue drain into pre-collecting and collecting lymphatic vessels that empty into regional lymph nodes and finally transit extracellular fluid back into circulation via the thoracic duct. Peripheral tissues are innervated by efferent fibres from the sympathetic branch of the autonomic nervous system. Autonomic neurons play a critical role in maintaining physiological homeostasis. They receive information integrated in the central nervous system (CNS) and communicate this via vertebral ganglia to control functions that are largely involuntary including heart rate, blood pressure, temperature and digestion.

Ordered tissue architecture is disrupted during cancer development which affects the structure and function of local and distant blood and lymphatic vessels to accelerate cancer progression [6, 7]. This review describes the role of lymphatic and blood vessels in metastasis and characterizes physiological factors that regulate their function, including inflammation and neural signals from the sympathetic nervous system (SNS). We describe therapeutic approaches that target molecular mediators of angiogenesis, lymphangiogenesis, and neural signalling, and discuss how these pro-metastatic molecules might be targeted in new anti-cancer drug combinations or novel clinical settings.

Angiogenesis and lymphangiogenesis

New blood and lymphatic vessels can form in and around tumours via the processes of angiogenesis and lymphangiogenesis, respectively [7]. During angiogenesis, endothelial cells that line pre-existing blood vessels are released from the extracellular matrix to form tip cells which lead a stalk of proliferating endothelial cells to reform as a new vessel [8]. Angiogenesis and lymphangiogenesis play critical roles in epithelial tumour progression by facilitating key steps in metastasis including tumour cell escape from the primary tumour and metastatic colonization of distant organs [9]. Metastasis is a complex multistep process that requires establishment of angiogenesis and evasion of the host immune defences for successful colonization of distant organs [10]. Metastasis begins with local invasion of the surrounding parenchyma by cancer cells followed by intravasation into nearby blood or lymphatic vessels. Both angiogenesis and lymphangiogenesis contribute to metastasis by providing new blood capillaries and initial lymphatics that tumour cells can use as entry points for dissemination [11, 12]. Tumour cells may traffic through these vessels to distant lymph nodes or distant organs where metastasis requires extravasation into the surrounding parenchyma. Successful colonization depends on development of a micrometastasis and finally the formation of a macrometastasis with localized angiogenesis providing new tumour-associated vasculature [9].

While much attention in recent times has been directed towards the formation of new vessels in a growing tumour, recent studies have also highlighted that molecular remodelling and re-differentiation of pre-existing vessels, without the formation of new vessels, contributes to metastasis [11, 13]. In response to angiogenic and lymphangiogenic stimuli, blood vessel capillaries and initial lymphatic vessels undergo sprouting angiogenesis and lymphangiogenesis, while larger blood and lymphatic vessels (eg. arteries or collecting lymphatics) undergo dilation and remodelling of the supporting smooth muscle cells. These changes in vascular structures promote increased lymph flow, dissemination of tumour cells and metastasis to regional lymph nodes [6, 12].

Neural signalling

In response to stressful conditions, SNS nerve fibres convey information from the CNS to the periphery to mediate the flight-or-flight response to threat [14]. Increasing evidence indicates that these neural signals also remodel the tumour microenvironment in ways that promote cancer progression. SNS fibres innervate organs that support growth of primary and metastatic secondary tumours, including lung, liver, lymphoid tissues and bone marrow. Chronic stress induces the release of the catecholaminergic neurotransmitter noradrenaline from these nerve fibres and invokes systemic release of adrenaline from the adrenal medulla. Stress neurotransmitters bind beta-adrenergic receptors on target cells and induce a signalling cascade through cAMP synthesis and protein kinase A phosphorylation to modulate cellular transcriptional programs. In addition to regulating neurotransmitter release, chronic stress also remodels neural architecture to increase the density of nerve fibres in peripheral organs, which may serve to amplify adrenergic signalling in stressed individuals [15]. Beta-adrenergic receptors are present on tumour cells and stromal cells in the tumour microenvironment [16-20], suggesting that tumour dynamics may be responsive to adrenergic stress response signalling.

In vivo studies have provided persuasive evidence that beta-adrenergic signalling promotes cancer progression. Beta-adrenergic activation by chronic physiological stress or by pharmacological beta-agonists increased spontaneous metastasis from primary mammary tumours to clinically relevant target organs including lymph node, lung and bone [20-23]. Adrenergic stress signalling had minimal effect on primary tumour growth rates in models of breast cancer [20, 30], but increased metastatic growth in mouse models of ovarian cancer and prostate cancer [24-27] and increased lymphatic colonization by tumour cells in a model of acute lymphoblastic leukemia [28, 29]. Of potential clinical importance, beta-blockers prevented metastasis suggesting a novel avenue for therapeutic intervention [20, 21, 24, 27, 31].

The effect of chronic stress on cancer progression in patients has been more challenging to define. Epidemiological studies and a meta-analysis of 131 prospective studies linked chronic stress to progression of established breast cancers [32-38] and a psychosocial intervention that sought to buffer stress showed improved cancer-related outcomes [39, 40]. However, few consistent relationships have been found between stress and the initial incidence of breast cancer [41-45]. Consistent with a key role for beta-adrenergic signalling in the pro-tumour effects of stress, recent epidemiological studies show that beta-blocker usage at the time of diagnosis is associated with improved outcomes in multiple tumour types (reviewed below, see Table 1). These studies highlight the emerging importance of stress response pathways in influencing cancer progression and suggest that effective disease management may include consideration of the whole patient, including their experience of chronic stress and other psychosocial factors.

2. Molecular Mediators of Cancer Progression

Molecular cross-talk between tumour cells and stromal cells induces the synthesis of pro-inflammatory mediators, growth factors and chemokines to create a microenvironment that is permissive for angiogenesis, lymphangiogenesis and tumour progression [46]. Inflammatory mediators play a pivotal role in growth and remodelling of blood and lymphatic vessels in and around the tumour, which impacts the local immune response and tumour cell dissemination. Specifically, inflammatory cells including M2-oriented macrophages and neutrophils are recruited to the tumour and release molecules including prostaglandins (PG), cytokines, chemokines and proteases which regulate angiogenesis and lymphangiogenesis and modulate cancer cell adhesion, migration and invasion to promote metastasis [47]. Neural signalling provides a higher level of physiological control to regulate inflammation and tumour cell dissemination [20, 31].

Angiogenesis

Oncogenic signalling, hypoxia and inflammation in the tumour microenvironment induce secretion of angiogenic factors by tumour cells or tumour stroma [4, 48]. The best validated tumour angiogenic factor is the glycoprotein vascular endothelial growth factor (VEGF)-A (also known as VEGF or vascular permeability factor) [49], which is induced by hypoxia and induces sprouting and proliferation of blood vascular endothelial cells via VEGF receptor-2 (VEGFR-2), a tyrosine kinase on the surface of these cells [50]. VEGFR-2 activation signals for other facets of angiogenesis such as remodelling of extracellular

matrix by matrix metalloproteinases [51] and integrins [52], endothelial cell guidance through semaphorins, ephrins, slits and their cognate receptors [48], through Delta-like 4/Notch signalling [53], and vessel formation and recruitment of pericytes (involving platelet-derived growth factors (PDGFs) [54]) (see [48] for overview). Alternative tumour angiogenic factors have been characterized in animal models, and are expressed in human cancers, including fibroblast growth factors (FGFs) [55], placenta growth factor (PlGF) [56, 57], angiopoietins [58], VEGF-C [59-61] and VEGF-D [62-64]. The importance of these alternative angiogenic proteins in prevalent human cancers remains to be established in clinical trials with agents specifically targeting these molecules. This complex signalling generates a tumour vasculature which is tortuous and leaky, but nevertheless able to facilitate tumour growth and spread.

Lymphangiogenesis

Tumour cells and stromal cells secrete VEGF-C and VEGF-D which drive lymphangiogenesis or lymphatic remodelling in the tumour microenvironment. These growth factors can be proteolytically activated [65-69] leading to high-affinity binding of VEGFR-3 to promote lymphangiogenesis involving initial lymphatic vessels, and VEGFR-2 which promotes circumferential expansion of initial lymphatics [7, 70-74]. VEGF-C and VEGF-D mediated lymphangiogenesis that promoted metastasis to lymph nodes [61, 62, 75] and distant organs [76, 77] in animal models, and their expression in human cancers correlated with metastasis and poor outcome (for review see [78, 79]). Furthermore, VEGF-C promoted lymphangiogenesis in distant lymph nodes, even before the onset of metastasis, which may facilitate metastasis beyond sentinel lymph nodes [80]. In addition to their effects on the growth of new blood vessels, VEGF-C and VEGF-D promoted dilation of tumour-draining collecting lymphatics, via VEGFR-2 and VEGFR-3 signalling and prostaglandin-dependent mechanisms, which facilitated lymph node metastasis [13]. Hence, VEGF-C and VEGF-D modulate the growth and structure of different types of lymphatic vessels to promote metastasis which led to the notion of targeting VEGF-C/VEGF-D/VEGFR-3 signalling in cancer [6, 81-83].

Other secreted proteins have been reported to promote lymphangiogenesis including VEGF-A, FGF-2, angiopoietin-2, insulin-like growth factor-1 and -2, PDGF-B, hepatocyte growth factor and erythropoietin [84, 85]. There is emerging evidence that some of these proteins play roles in tumour lymphangiogenesis [86, 87], but their effects on lymphogenous metastasis require further characterization.

Inflammation and lymphangiogenesis

PGs play a key role in creating an inflammatory environment that supports angiogenesis and lymphangiogenesis in tumours. PGs are bioactive lipids that are produced from arachidonic acid by the actions of cyclooxygenases (COX) in a wide variety of human tissue and have a central role in inflammation and cancer progression [88, 89]. Two COX isoforms are responsible for PG biosynthesis. COX-1 is constitutively expressed in most tissues and is important in maintaining basal PG levels, whereas COX-2 is induced in tissues during inflammation and cancer. Consequently, COX-2 is up-regulated by inflammatory mediators in many types of cancers including breast, colon, lung, pancreas, and head and neck cancers

[90-98]. PG synthesis is balanced by 15-hydroxyprostaglandin dehydrogenase (PGDH), which degrades PG [99]. Expression of PGDH was shown to be abrogated in animal models of colon cancer suggesting that PGDH is a tumour suppressor [100-102]. The pro-tumourigenic effects of COX-2 are believed to be largely attributed to its role in producing PGE2 [103, 104]. PGE2 exerts its effects via prostaglandin E receptors (EP)1-4 G-protein coupled receptors [105]. Tumour studies conducted in EP receptor knockout animals or using pharmacological inhibition revealed that these receptors contribute to tumour angiogenesis and lymphangiogenesis [106-110]. PGs are released by tumour cells and stromal cells, and play a central role in the tumour inflammatory response by down-regulating anti-neoplastic cytokines tumour necrosis factor-alpha (TNF- α) and interferon-gamma (IFN γ) whilst up-regulating immunosuppressive cytokines including interleukin (IL)-10, IL-4 and IL-6 [111, 112]. PGE2 promotes tumour immunosuppression by inhibiting maturation of cytotoxic T cells [113] and increasing migration of dendritic cells to lymph nodes [114]. Naïve T cells fail to respond to tumour-derived antigens presented by dendritic cells or antigen presenting cells, which enhances tumour cell evasion of host immune defences and permits metastatic dissemination through blood or lymphatic vasculature.

The link between the VEGF family members and inflammatory PG signalling pathways was first observed in animal models of colon cancer, where an association between COX-2, VEGF-A expression and angiogenesis was demonstrated [115, 116]. PG signalling by stromal cells including fibroblasts and endothelial cells was also shown to contribute to angiogenesis [108, 117, 118]. Clinical studies have demonstrated a correlation between the level of COX-2 expression and the extent of angiogenesis in breast, endometrial and gastric cancers [119-121]. Likewise, clinical and histopathological studies have revealed a correlation between COX-2 expression, lymphatic vessel density and lymph node metastasis in several human cancer types [122-124]. The PG pathway can influence lymphatic vessel density and therefore lymph node metastasis by regulating the levels of VEGF-C and VEGF-D produced within both the tumour and tumour stroma [125-127]. PGE2 mediates this effect by acting via different EP receptors expressed on the surface of various tumour or stromal cells. Activation of EP3 caused an increase in VEGF-C and VEGF-D secretion by cultured macrophages whereas EP4 activation elevated VEGF-C secretion by tumour-associated macrophages and VEGF-D secretion by tumour-associated fibroblasts leading to enhanced lymphangiogenesis within the primary tumour [127]. In addition, local secretion of PG by endothelial cells can also affect the morphology of the lymphatics by dilation and can facilitate the dissemination of cancer cells to draining lymph nodes [13]. These findings suggest that inhibition of PG synthesis by pharmacological or therapeutic targeting of the VEGF-C/VEGF-D signalling pathway might slow cancer progression.

Neural regulation of angiogenesis and metastasis

Neural signalling through beta-adrenergic pathways was recently identified as a physiological regulator of angiogenesis and metastasis [20, 24]. Activation of beta-adrenergic receptors through physiological or pharmacological stimuli induces a pro-metastatic gene expression signature in the tumour microenvironment, remodels primary tumour architecture and increases the frequency of tumour cell escape [20, 24-26, 28]. Physiological activation of stress pathways using repeated restraint in mouse models of

breast and ovarian cancer resulted in genetic switching with transcriptional upregulation of angiogenesis genes including *Vegf-a*, and increased blood vessel density [19, 20, 24, 128]. Regulation of inflammation plays a central role in beta-adrenergic regulation of angiogenesis. The effect of stress on angiogenesis was dependent on recruitment of macrophages to the primary tumour [20], suggesting an intimate relationship between neural signalling, tumour-associated inflammation and angiogenesis. Consistent with this, several lines of evidence suggest that macrophages are particularly sensitive to adrenergic signalling [20, 129, 130]. Noradrenaline increased MMP9 production by cultured macrophages [130]. Similarly, significant life stress prior to diagnosis with ovarian cancer was associated with increased MMP9 production by CD68+ cells in primary tumours [130], which has been associated with aggressive tumour progression likely due to altered basement membrane integrity.

The adverse effects of stress on angiogenesis may be reversed by alternate neurotransmitter signalling, although the clinical application of this is unclear. Dopamine was found to act on tumour cells and pericytes to reverse stress-induced angiogenesis and increase pericyte coverage to stabilize blood vessels [131]. The effect of stress response pathways on lymphangiogenesis has not been evaluated. However, beta-adrenergic regulation of both PG synthesis and normal lymphatic development and lymphatic flow [132, 133] suggest that neural signalling may regulate tumour-associated lymphangiogenesis.

In addition to modulating the tumour microenvironment, neural signalling may impact metastasis by directly modulating invasive, inflammatory and anti-apoptotic behavior by tumour cells. Tumour cells express beta-adrenergic receptors, and receptor levels have been associated with adverse outcomes [16, 17]. Beta-adrenergic signalling increases expression of inflammatory cytokines including IL-6 and IL-8 by tumour cells [19, 134] and drives invasion of cancer cells in culture assays [135-137]. Beta-adrenergic activation promoted ovarian cancer cell resistance to anoikis through focal adhesion kinase-mediated pathways [138] and protected cells against chemotherapy induced apoptosis [26, 139].

3. Drugs that Target Angiogenesis and Lymphangiogenesis

Anti-angiogenics and anti-lymphangiogenics

Various targeted anti-angiogenic agents have been approved by the U.S. Food and Drug Administration for clinical use in oncology, most of which target VEGF-A/VEGFR-2 signalling with varying degrees of specificity [140](Figure 1). The first was bevacizumab (also known as Avastin), a humanized neutralizing anti-VEGF-A monoclonal antibody used to treat multiple cancers, typically in combination with cytotoxic chemotherapy [141]. The observed lack of efficacy of bevacizumab as a single agent led to the suggestion that it may be more effectively utilized as a chemosensitization agent by enhancing entry of chemotherapeutics into tumours, consequent to bevacizumab-induced vascular normalization [142].

Other anti-angiogenic agents in oncology include Aflibercept ("VEGF Trap"), a soluble receptor which binds VEGF-A, VEGF-B and PlGF, that was recently approved for treatment of metastatic colorectal cancer [143]. Various small molecule protein kinase inhibitors

(PKIs) which target VEGFR-2 and other kinases have been approved, including pazopanib (Votrient), vandetanib (Zactima), sunitinib (Sutent) and sorafenib (Nexavar) [140]. PKIs typically target multiple kinases which can enhance efficacy but lead to side-effects. The resulting dose-limiting toxicities have restricted PKI use in oncology due to difficulties combining PKIs with cytotoxic chemotherapeutics. A challenge associated with anti-angiogenic agents is emergence of drug resistance during treatment, hence considerable effort is being made to define mechanisms of resistance that may lead to improved treatment strategies [140, 144].

The concept of targeting tumour lymphangiogenesis to restrict metastasis arose more recently than that for anti-angiogenesis, so development of anti-lymphangiogenic drugs is less advanced. Nevertheless, a range of inhibitors targeting VEGF-C/VEGF-D/VEGFR-3 signalling have been developed for blocking tumour lymphangiogenesis. These include neutralizing monoclonal antibodies against VEGF-C [77], VEGF-D [145], VEGFR-3 [146], Neuropilin-2 (a co-receptor for VEGF-C and VEGF-D [147]), and soluble versions of VEGFR-3 that sequester VEGF-C and VEGF-D [148]. Notably, anti-VEGF-C and anti-VEGFR-3 monoclonal antibodies recently progressed to phase I clinical trial. Other potential anti-lymphangiogenic therapeutics include antibodies and small molecules targeting Angiopoietin/Tie2 signalling [149]. Further, small molecule PKIs targeting VEGFR-2 and VEGFR-3 or Tie2 have been developed [150-154]. The exact clinical settings in which these drugs would be used in oncology will require careful consideration of tumour type and timing of treatment relative to surgery and other therapeutic interventions [81].

NSAIDs

NSAIDs are a diverse group of drugs that have been traditionally used to treat inflammatory disease. These drugs alter PG levels by regulating the activity of COX enzymes and are used during surgery as analgesics and for pain management post-surgery. NSAIDs include selective inhibitors against COX-1 (eg. Ketoprofen) or COX-2 (eg. Celecoxib, Etodolac and Rofecoxib) or non-selective drugs that inhibit both COX enzymes (eg. Aspirin, Naproxen and Ibuprofen) [155]. While some experimental evidence suggested anti-cancer effects of NSAIDs, recent clinical trial data have shown a significant link between NSAID intake and restricted cancer development [115, 156-158]. Data further suggested this effect was at the level of preventing metastasis [159].

By inhibiting PG synthesis, NSAIDs have profound effects on key characteristics of tumourigenesis, including cell proliferation, migration, apoptosis and angiogenesis [155]. Epidemiologic studies found long-term use of NSAIDs was associated with reduced risk of breast, colon, lung and prostate cancer and recurrence [160-162]. Consistent with this, clinical trials revealed that NSAIDs restricted tumour progression in breast and prostate cancer patients [159, 161, 163-166]. To define the cellular and molecular mechanisms by which NSAIDs restrict metastasis, the impact was assessed on both lymphangiogenic growth factor expression and structure of the lymphatic vasculature in pre-clinical models of metastatic disease. *In vitro* treatment of breast and esophageal cancer cell lines with Nimesulide, Diclofenac, Rofecoxib or SC-5600 induced a down-regulation of VEGF-C

expression [167, 168]. In a model of gastric cancer, treatment with a COX-2 inhibitor, Etodolac, reduced lymphangiogenesis which decreased metastasis to sentinel lymph nodes.

NSAIDs regulate lymphangiogenesis by reducing macrophage secretion of VEGF-C to modulate lymphatic vessel density and by modulating the morphology of lymphatic collector vessels that facilitated metastasis [13, 126, 169, 170]. While most clinical trials involving NSAIDs have emphasized tumour growth, mortality and metastasis, future clinical trials evaluating the efficacy of NSAIDs on tumour metastasis should focus on clinical evaluations of tumour lymphatics.

Beta-blockers

Beta-adrenergic regulation of cancer progression suggests that inhibiting adrenergic stress response pathways with beta-blockers might protect against metastasis and cancer progression. Sir James W. Black developed the beta-blocker propranolol in 1964 [171] and in 1975 founded the first clinical trial of beta-blockers for heart failure. Beta-blockade revolutionized the medical treatment of heart disease including hypertension, arrhythmias and angina, and is used peri-operatively to maintain physiological homeostasis. Beta-blockers bind beta-adrenergic receptors and prevent activation by endogenous catecholaminergic neurotransmitters. Beta-blockers can therefore regulate the effects of SNS signalling on heart and smooth muscle contractility. Due to their ability to block stress neurotransmitter signalling at the cellular level, beta-blockers may also be a novel anti-cancer therapeutic strategy for targeted blockade of the stress responsive pathways.

The peri-operative period may be particularly sensitive to stress biology, and offer opportunity for novel application of NSAIDs and beta-blockers. Surgical stress increased retention of tumour cells in lung in rodent models of breast cancer [23, 31] and increased tumour growth in ovarian cancer models [172]. Induction of inflammation with PGE2 increased tumour cell retention and promoted an immunosuppressive environment by decreasing natural killer cell activity [31]. COX inhibitors and beta-blockers both reduced tumour cell retention, but the effect was additive when the drugs were combined [31].

Combined Propranolol and Etodolac treatment also increased survival rates in mice following tumour excision [173]. NSAIDs and beta-blockers are already used in the peri-operative setting to limit inflammation and regulate heart rate and blood pressure. These findings suggest that peri-operative use of NSAIDs in combination with beta-blockers may provide opportunities to improve immune competence and reduce the risk of tumour metastasis.

In addition to the pre-clinical studies described above indicating that beta-blockade slows progression of multiple tumour types, epidemiological studies suggest beta-blockers may protect patients against the progression of cancer. Many of these large retrospective cohort studies found that beta-blocker usage for co-morbid hypertension was associated with improved cancer-related outcomes, including increased metastasis-free survival and negative lymphovascular status [174, 175] (see Table 1). In contrast, use of other anti-hypertensive medications including angiotensin converting enzyme inhibitors or calcium channel blockers were not associated with beneficial effects [176-180]. Metoprolol and atenolol were the

most frequently prescribed beta-blockers in these studies, followed by non-selective propranolol. Drug exposure varied with some studies looking at associations of beta-blocker usage prior to diagnosis while others investigated beta-blockade concurrent with neoadjuvant chemotherapy.

It is unclear if all beta-blockers protect equally against cancer progression. Pre-clinical studies suggest signalling through beta2-adrenergic receptors promote cancer progression but few studies have investigated the effect of signalling through beta1- or beta3-adrenergic receptors [24]. Antagonists that show mild selectivity towards beta1-adrenergic receptor including metoprolol and atenolol (2-5 fold selectivity for beta1 over beta2-adrenergic receptors) are now more frequently prescribed than the older generation of non-specific beta-blockers. It will be critical to define receptors that mediate beta-adrenergic effects on cancer prior to randomized clinical trials. Similarly, not all tumour types may be equally responsive to beta-blockade. Beta-blocker use was associated with favorable outcomes in women with triple negative breast cancer [174, 175], but not those with ER+ cancer. Beta-blocker use was associated with reduced prostate-cancer specific mortality in men who received androgen deprivation therapy, but not in those with androgen refractory tumours [181, 182]. Randomized trials of target populations will be required to validate these observations, however, they suggest that adrenergic signalling may interact with other signalling pathways in tumours to affect progression.

4. Future Directions

The bidirectional relationship between tumour cells and their microenvironment provides novel opportunities for interventions to slow or stop cancer progression (Figure 2). Tumour-related angiogenesis and lymphangiogenesis have critical roles in tumour cell dissemination, and are tightly regulated by inflammatory and neural signals in the immediate microenvironment. This provides opportunities to slow or prevent metastasis by complementing existing anti-angiogenic therapies with interventions that modulate immune cell recruitment or function, or drugs that modulate peripheral neural signalling.

Targeting SNS signalling may provide a novel leverage point for new anti-cancer therapies. Translation of findings from recent pre-clinical and epidemiological studies of beta-blockers to the cancer clinic requires characterization of the receptors and downstream signalling pathways that mediate beta-adrenergic control of metastasis. The variable outcomes of clinical observational studies (see Table 1) indicate that not all patients or tumour types may be sensitive to beta-blockade and not all beta-blockers may provide protective effects against cancer progression. Prospective randomized clinical trials will be essential for unbiased assessment of beta-blockade in specific patient cohorts. Comprehensive and systematic profiling of beta-adrenergic signalling in tumour cells and in tumour stromal cells is needed to provide a mechanistic framework for rational selection and development of beta-blockers to treat cancer. These pharmacobiological studies may additionally identify biomarkers of tumours that are sensitive to beta-adrenergic intervention to identify cancer patients who will optimally benefit from beta-blockade.

The use of drug combinations that target multiple metastatic processes including angiogenesis or lymphangiogenesis, neural signalling and inflammation may be effective in slowing or reversing cancer progression. The results of trials of small molecule inhibitors and monoclonal antibodies that target VEGF-dependent angiogenesis have shown some success and are now FDA approved for a range of cancer indications [183]. Nonetheless the heterogeneity of the response in patients and the development of resistance means that further studies are required to gain the most patient benefit from anti-angiogenic strategies. Patient profiling of molecular angiogenic drivers may allow more selective use of anti-angiogenic drugs, and combination with anti-inflammatory drugs or beta-blockers may provide additional therapeutic support. Beta-blockade may also enhance efficacy of chemotherapy by increasing tumour cell apoptosis [26, 184] and through modulation of immune cell recruitment to tumours [20], which has been linked to chemotherapy resistance [185]. In addition to maintaining homeostasis, NSAIDs and beta-blockers use in the peri-operative setting may reduce the risk of tumour metastasis. In future, rational selection of these drugs and their application in specific patient populations may improve cancer outcomes.

Insights from vascular and neural biology have demonstrated the developmental links between the blood vascular, lymphatic vasculature and the peripheral nervous system. These relationships extend to pathologies including cancer, where stress responses modify angiogenic and lymphangiogenic responses to facilitate cancer progression. Knowledge of these relationships opens the way for evaluation of a number of well accepted therapeutic agents to be used in preventative or peri-operative strategies to combat cancer.

Acknowledgments

M.G.A. and S.A.S. are supported by Research Fellowships and a Program Grant from the National Health and Medical Research Council of Australia. E.K.S is a National Breast Cancer Foundation Early Career Fellow and is supported by National Health and Medical Research Council of Australia (1008865, 1049561), National Institutes of Health (CA160890), Monash Institute of Pharmaceutical Sciences and the UCLA Norman Cousins Center. C.P.L is supported by a PhD scholarship from Cancer Therapeutics Co-operative Research Centre. We apologise to authors whose work could not be quoted due to space limitations.

REFERENCES

1. Bhowmick NA, Neilson EG, Moses HL. Stromal fibroblasts in cancer initiation and progression. *Nature (London)*. 2004; 432(7015):332–337. [PubMed: 15549095]
2. Macheda ML, Stacker SA. Importance of Wnt signaling in the tumor stroma microenvironment. *Current Cancer Drug Targets*. 2008; 8(6):454–65. [PubMed: 18781892]
3. Hanahan D, Coussens LM. Accessories to the crime: functions of cells recruited to the tumor microenvironment. *Cancer Cell*. 2012; 21(3):309–22. [PubMed: 22439926]
4. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. *Cell*. 2011; 144(5):646–74. [PubMed: 21376230]
5. Carmeliet P. Blood vessels and nerves: common signals, pathways and diseases. *Nat.Rev.Genet*. 2003; 4(9):710–720. [PubMed: 12951572]
6. Alitalo K. The lymphatic vasculature in disease. *Nature Med*. 2011; 17(11):1371–80. [PubMed: 22064427]
7. Achen MG, McColl BK, Stacker SA. Focus on lymphangiogenesis in tumor metastasis. *Cancer Cell*. 2005; 7(2):121–127. [PubMed: 15710325]

8. Adams RH, Alitalo K. Molecular regulation of angiogenesis and lymphangiogenesis. *Nature. Rev. Mol. Cell Biol.* 2007; 8(6):464–478. [PubMed: 17522591]
9. Fidler IJ. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. *Nature Rev.Cancer.* 2003; 3(6):453–458. [PubMed: 12778135]
10. Fidler IJ. The biology of cancer metastasis. *Semin Cancer Biol.* 2011; 21(2):71. [PubMed: 21145967]
11. Farnsworth RH, et al. Vascular remodeling in cancer. *Oncogene.* 2013
12. Stacker SA, et al. Lymphangiogenesis and cancer metastasis. *Nat.Rev.Cancer.* 2002; 2:573–583. [PubMed: 12154350]
13. Karnezis T, et al. VEGF-D promotes tumor metastasis by regulating prostaglandins produced by the collecting lymphatic endothelium. *Cancer Cell.* 2012; 21(2):181–95. [PubMed: 22340592]
14. Cannon WM. Official Medical Experts. *Cal State J Med.* 1915; 13(1):13–5. [PubMed: 18736469]
15. Sloan EK, et al. Social stress enhances sympathetic innervation of primate lymph nodes: mechanisms and implications for viral pathogenesis. *J Neurosci.* 2007; 27(33):8857–65. [PubMed: 17699667]
16. Powe DG, et al. Alpha- and beta-adrenergic receptor (AR) protein expression is associated with poor clinical outcome in breast cancer: an immunohistochemical study. *Breast Cancer Res Treat.* 2011; 130:457–463. [PubMed: 21298476]
17. Shi M, et al. The beta2-adrenergic receptor and Her2 comprise a positive feedback loop in human breast cancer cells. *Breast Cancer Res Treat.* 2011; 125(2):351–62. [PubMed: 20237834]
18. Moretti S, et al. beta-adrenoceptors are upregulated in human melanoma and their activation releases pro-tumorigenic cytokines and metalloproteases in melanoma cell lines. *Lab Invest.* 2013; 93(3):279–90. [PubMed: 23318885]
19. Yang EV, et al. Norepinephrine upregulates VEGF, IL-8, and IL-6 expression in human melanoma tumor cell lines: implications for stress-related enhancement of tumor progression. *Brain Behav Immun.* 2009; 23(2):267–75. [PubMed: 18996182]
20. Sloan EK, et al. The sympathetic nervous system induces a metastatic switch in primary breast cancer. *Cancer Res.* 2010; 70(18):7042–52. [PubMed: 20823155]
21. Campbell JP, et al. Stimulation of host bone marrow stromal cells by sympathetic nerves promotes breast cancer bone metastasis in mice. *PLoS Biol.* 2012; 10(7):e1001363. [PubMed: 22815651]
22. Ben-Eliyahu S, et al. Stress increases metastatic spread of a mammary tumor in rats: evidence for mediation by the immune system. *Brain Behav Immun.* 1991; 5(2):193–205. [PubMed: 1654166]
23. Ben-Eliyahu S, et al. Suppression of NK cell activity and of resistance to metastasis by stress: a role for adrenal catecholamines and beta-adrenoceptors. *Neuroimmunomodulation.* 2000; 8(3):154–64. [PubMed: 11124582]
24. Thaker PH, et al. Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. *Nat Med.* 2006; 12(8):939–44. [PubMed: 16862152]
25. Magnon C, et al. Autonomic nerve development contributes to prostate cancer progression. *Science.* 2013; 341(6142):1236361. [PubMed: 23846904]
26. Hassan S, et al. Behavioral stress accelerates prostate cancer development in mice. *J Clin Invest.* 2013; 123(2):874–86. [PubMed: 23348742]
27. Palm D, et al. The norepinephrine-driven metastasis development of PC-3 human prostate cancer cells in BALB/c nude mice is inhibited by beta-blockers. *Int J Cancer.* 2006; 118(11):2744–9. [PubMed: 16381019]
28. Lamkin DM, et al. Chronic stress enhances progression of acute lymphoblastic leukemia via beta-adrenergic signaling. *Brain Behav Immun.* 2012; 26(4):635–41. [PubMed: 22306453]
29. Inbar S, et al. Do stress responses promote leukemia progression? An animal study suggesting a role for epinephrine and prostaglandin-E2 through reduced NK activity. *PLoS One.* 2011; 6(4):e19246. [PubMed: 21559428]
30. Perez Pinero C, et al. Involvement of alpha2- and beta2-adrenoceptors on breast cancer cell proliferation and tumour growth regulation. *Br J Pharmacol.* 2012; 166(2):721–36. [PubMed: 22122228]

31. Benish M, et al. Perioperative use of beta-blockers and COX-2 inhibitors may improve immune competence and reduce the risk of tumor metastasis. *Ann Surg Oncol.* 2008; 15(7):2042–52. [PubMed: 18398660]
32. Chida Y, et al. Do stress-related psychosocial factors contribute to cancer incidence and survival? *Nat Clin Pract Oncol.* 2008
33. Kroenke CH, et al. Social networks, social support, and survival after breast cancer diagnosis. *J Clin Oncol.* 2006; 24(7):1105–11. [PubMed: 16505430]
34. Reynolds P, et al. Use of coping strategies and breast cancer survival: results from the Black/White Cancer Survival Study. *Am J Epidemiol.* 2000; 152(10):940–9. [PubMed: 11092436]
35. Ell K, et al. Social relations, social support and survival among patients with cancer. *J Psychosom Res.* 1992; 36(6):531–41. [PubMed: 1640391]
36. Soler-Vila H, Kasl SV, Jones BA. Prognostic significance of psychosocial factors in African-American and white breast cancer patients: a population-based study. *Cancer.* 2003; 98(6):1299–308. [PubMed: 12973855]
37. Barraclough J, et al. Life events and breast cancer prognosis. *BMJ.* 1992; 304(6834):1078–81. [PubMed: 1586819]
38. Graham J, et al. Stressful life experiences and risk of relapse of breast cancer: observational cohort study. *British Medical Journal.* 2002; 324(7351):1420. [PubMed: 12065263]
39. Andersen BL, et al. Biobehavioral, immune, and health benefits following recurrence for psychological intervention participants. *Clin Cancer Res.* 2010; 16(12):3270–8. [PubMed: 20530702]
40. Andersen BL, et al. Psychologic intervention improves survival for breast cancer patients: a randomized clinical trial. *Cancer.* 2008; 113(12):3450–8. [PubMed: 19016270]
41. Lillberg K, et al. Stressful life events and risk of breast cancer in 10,808 women: a cohort study. *Am J Epidemiol.* 2003; 157(5):415–23. [PubMed: 12615606]
42. Ewertz M. Bereavement and breast cancer. *Br J Cancer.* 1986; 53(5):701–3. [PubMed: 3718825]
43. Levav I, et al. Cancer incidence and survival following bereavement. *Am J Public Health.* 2000; 90(10):1601–7. [PubMed: 11029995]
44. Johansen C, Olsen JH. Psychological stress, cancer incidence and mortality from non-malignant diseases. *Br J Cancer.* 1997; 75(1):144–8. [PubMed: 9000613]
45. Kvikstad A, et al. Widowhood and divorce related to cancer risk in middle-aged women. A nested case-control study among Norwegian women born between 1935 and 1954. *Int J Cancer.* 1994; 58(4):512–6. [PubMed: 8056447]
46. Wang D, Dubois RN. The role of COX-2 in intestinal inflammation and colorectal cancer. *Oncogene.* 2010; 29(6):781–8. [PubMed: 19946329]
47. Mantovani A, Pierotti MA. Cancer and inflammation: a complex relationship. *Cancer Lett.* 2008; 267(2):180–1. [PubMed: 18562089]
48. Weis SM, Cheresh DA. Tumor angiogenesis: molecular pathways and therapeutic targets. *Nat Med.* 2011; 17(11):1359–70. [PubMed: 22064426]
49. Ferrara N. Vascular endothelial growth factor. *Arterioscler. Thromb. Vasc. Biol.* 2009; 29(6):789–91. [PubMed: 19164810]
50. Millauer B, et al. High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis. *Cell.* 1993; 72:835–846. [PubMed: 7681362]
51. Gialeli C, Theocharis AD, Karamanos NK. Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. *FEBS J.* 2011; 278(1):16–27. [PubMed: 21087457]
52. Silletti S, et al. Disruption of matrix metalloproteinase 2 binding to integrin $\alpha_5\beta_3$ by an organic molecule inhibits angiogenesis and tumor growth in vivo. *Proc.Natl.Acad.Sci.USA.* 2001; 98(1):119–124. [PubMed: 11134507]
53. Kofler NM, et al. Notch signaling in developmental and tumor angiogenesis. *Genes Cancer.* 2011; 2(12):1106–16. [PubMed: 22866202]

54. Abramsson A, Lindblom P, Betsholtz C. Endothelial and nonendothelial sources of PDGF-B regulate pericyte recruitment and influence vascular pattern formation in tumors. *J. Clin. Invest.* 2003; 112(8):1142–51. [PubMed: 14561699]
55. Brooks AN, Kilgour E, Smith PD. Molecular pathways: fibroblast growth factor signaling: a new therapeutic opportunity in cancer. *Clin. Cancer Res.* 2012; 18(7):1855–62. [PubMed: 22388515]
56. Fischer C, et al. Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. *Cell.* 2007; 131(3):463–75. [PubMed: 17981115]
57. Snuderl M, et al. Targeting placental growth factor/neuropilin 1 pathway inhibits growth and spread of medulloblastoma. *Cell.* 2013; 152(5):1065–76. [PubMed: 23452854]
58. Gerald D, et al. Angiopoietin-2: an attractive target for improved antiangiogenic tumor therapy. *Cancer Res.* 2013; 73(6):1649–57. [PubMed: 23467610]
59. Salven P, et al. Vascular endothelial growth factors VEGF-B and VEGF-C are expressed in human tumors. *Am. J. Pathol.* 1998; 153:103–108. [PubMed: 9665470]
60. Valtola R, et al. VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancer. *Am. J. Pathol.* 1999; 154(5):1381–1390. [PubMed: 10329591]
61. Skobe M, et al. Concurrent induction of lymphangiogenesis, angiogenesis, and macrophage recruitment by vascular endothelial growth factor-C in melanoma. *Am. J. Pathol.* 2001; 159(3): 893–903. [PubMed: 11549582]
62. Stacker SA, et al. VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. *Nature Med.* 2001; 7(2):186–91. [PubMed: 11175849]
63. Debinski W, et al. VEGF-D is an X-linked/AP-1 regulated putative onco-angiogen in human glioblastoma multiforme. *Mol. Med.* 2001; 7:598–608. [PubMed: 11778649]
64. Wise LM, et al. Viral vascular endothelial growth factors vary extensively in amino acid sequence, receptor-binding specificities, and the ability to induce vascular permeability yet Are uniformly active mitogens. *J. Biol. Chem.* 2003; 278(39):38004–38014. [PubMed: 12867434]
65. Stacker SA, et al. Biosynthesis of vascular endothelial growth factor-D involves proteolytic processing which generates non-covalent homodimers. *J. Biol. Chem.* 1999; 274(45):32127–36. [PubMed: 10542248]
66. Joukov V, et al. Proteolytic processing regulates receptor specificity and activity of VEGF-C. *EMBO J.* 1997; 16:3898–3911. [PubMed: 9233800]
67. McColl BK, et al. Plasmin activates the lymphangiogenic growth factors VEGF-C and VEGF-D. *J. Exp. Med.* 2003; 198(6):863–868. [PubMed: 12963694]
68. McColl BK, et al. Proprotein convertases promote processing of VEGF-D, a critical step for binding the angiogenic receptor VEGFR-2. *FASEB J.* 2007; 21(4):1088–1098. [PubMed: 17242158]
69. Baldwin ME, et al. Multiple forms of mouse vascular endothelial growth factor-D are generated by RNA splicing and proteolysis. *J. Biol. Chem.* 2001; 276(47):44307–44314. [PubMed: 11574540]
70. Joukov V, et al. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt-4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. *EMBO J.* 1996; 15(2):290–298. [PubMed: 8617204]
71. Achen MG, et al. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). *Proc. Natl. Acad. Sci. U.S.A.* 1998; 95(2):548–53. [PubMed: 9435229]
72. Veikkola T, et al. Signalling via vascular endothelial growth factor receptor-3 is sufficient for lymphangiogenesis in transgenic mice. *EMBO J.* 2001; 20(6):1223–31. [PubMed: 11250889]
73. Jeltsch M, et al. Hyperplasia of lymphatic vessels in VEGF-C transgenic mice. *Science.* 1997; 276:1423–1425. [PubMed: 9162011]
74. Wirzenius M, et al. Distinct vascular endothelial growth factor signals for lymphatic vessel enlargement and sprouting. *J. Exp. Med.* 2007; 204(6):1431–1440. [PubMed: 17535974]
75. Mandriota SJ, et al. Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis. *EMBO J.* 2001; 20(4):672–682. [PubMed: 11179212]
76. Kopfstein L, et al. Distinct roles of vascular endothelial growth factor-D in lymphangiogenesis and metastasis. *Am. J. Pathol.* 2007; 170(4):1348–61. [PubMed: 17392173]

77. Gogineni A, et al. Inhibition of VEGF-C modulates distal lymphatic remodeling and secondary metastasis. *PLoS One*. 2013; 8(7):e68755. [PubMed: 23874750]
78. Stacker SA, Williams RA, Achen MG. Lymphangiogenic growth factors as markers of tumor metastasis. *APMIS*. 2004; 112:539–549. [PubMed: 15563315]
79. Farnsworth RH, Achen MG, Stacker SA. Lymphatic endothelium: An important interactive surface for malignant cells. *Pulm.Pharmacol.Ther.* 2006; 19(1):51–60. [PubMed: 16286238]
80. Hirakawa S, et al. VEGF-C-induced lymphangiogenesis in sentinel lymph nodes promotes tumor metastasis to distant sites. *Blood*. 2007; 109(3):1010–7. [PubMed: 17032920]
81. Achen MG, Mann GB, Stacker SA. Targeting lymphangiogenesis to prevent tumour metastasis. *Br.J Cancer*. 2006; 94(10):1355–1360. [PubMed: 16641900]
82. Stacker SA, Achen MG. From anti-angiogenesis to anti-lymphangiogenesis: emerging trends in cancer therapy. *Lymphat. Res. Biol.* 2008; 6(3-4):165–72. [PubMed: 19093789]
83. Achen MG, Stacker SA. Molecular control of lymphatic metastasis. *Ann. N.Y. Acad. Sci.* 2008; 1131:225–34. [PubMed: 18519975]
84. Schulte-Merker S, Sabine A, Petrova TV. Lymphatic vascular morphogenesis in development, physiology, and disease. *J Cell Biol.* 2011; 193(4):607–18. [PubMed: 21576390]
85. Tammela T, Alitalo K. Lymphangiogenesis: Molecular mechanisms and future promise. *Cell*. 2010; 140(4):460–76. [PubMed: 20178740]
86. Lee AS, et al. Erythropoietin induces lymph node lymphangiogenesis and lymph node tumor metastasis. *Cancer Res.* 2011; 71(13):4506–17. [PubMed: 21586615]
87. Karpinich NO, et al. Adrenomedullin gene dosage correlates with tumor and lymph node lymphangiogenesis. *FASEB J.* 2013; 27(2):590–600. [PubMed: 23099649]
88. DuBois RN, et al. The nuclear eicosanoid receptor, PPARgamma, is aberrantly expressed in colonic cancers. *Carcinogenesis*. 1998; 19(1):49–53. [PubMed: 9472692]
89. Menter DG, Dubois RN. Prostaglandins in cancer cell adhesion, migration, and invasion. *Int J Cell Biol*. 2012. 2012:723419.
90. Yokoyama C, Takai T, Tanabe T. Primary structure of sheep prostaglandin endoperoxide synthase deduced from cDNA sequence. *FEBS Lett.* 1988; 231(2):347–51. [PubMed: 3129310]
91. Kujubu DA, et al. TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. *J Biol Chem.* 1991; 266(20):12866–72. [PubMed: 1712772]
92. Hla T, Neilson K. Human cyclooxygenase-2 cDNA. *Proc Natl Acad Sci U S A.* 1992; 89(16):7384–8. [PubMed: 1380156]
93. Eberhart GP, et al. Insulin sensitivity of adipocytes from inbred mouse strains resistant or sensitive to diet-induced obesity. *Am J Physiol.* 1994; 266:R1423–8. 5 Pt 2. [PubMed: 8203615]
94. Sano H, et al. Expression of cyclooxygenase-1 and -2 in human colorectal cancer. *Cancer Res.* 1995; 55(17):3785–9. [PubMed: 7641194]
95. Hida T, et al. Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. *Cancer Research.* 1998; 58(17):3761–3764. [PubMed: 9731479]
96. Hwang D, et al. Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer. *J Natl Cancer Inst.* 1998; 90(6):455–60. [PubMed: 9521170]
97. Tucker ON, et al. Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer. *Cancer Res.* 1999; 59(5):987–90. [PubMed: 10070951]
98. Chan G, et al. Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck. *Cancer Res.* 1999; 59(5):991–4. [PubMed: 10070952]
99. Tai HH, et al. Structure and function of human NAD(+)-linked 15-hydroxyprostaglandin dehydrogenase. *Adv Exp Med Biol.* 2002; 507:245–50. [PubMed: 12664592]
100. Backlund MG, Mann JR, Dubois RN. Mechanisms for the prevention of gastrointestinal cancer: the role of prostaglandin E2. *Oncology.* 2005; 69(Suppl 1):28–32. [PubMed: 16210874]
101. Yan M, et al. 15-Hydroxyprostaglandin dehydrogenase, a COX-2 oncogene antagonist, is a TGF-beta-induced suppressor of human gastrointestinal cancers. *Proc Natl Acad Sci U S A.* 2004; 101(50):17468–73. [PubMed: 15574495]

102. Wolf I, et al. 15-hydroxyprostaglandin dehydrogenase is a tumor suppressor of human breast cancer. *Cancer Res.* 2006; 66(15):7818–23. [PubMed: 16885386]
103. Rigas B, Goldman IS, Levine L. Altered eicosanoid levels in human colon cancer. *J Lab Clin Med.* 1993; 122(5):518–23. [PubMed: 8228569]
104. Pugh S, Thomas GA. Patients with adenomatous polyps and carcinomas have increased colonic mucosal prostaglandin E2. *Gut.* 1994; 35(5):675–8. [PubMed: 8200564]
105. Greenhough A, et al. The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. *Carcinogenesis.* 2009; 30(3):377–86. [PubMed: 19136477]
106. Sonoshita M, et al. Acceleration of intestinal polyposis through prostaglandin receptor EP2 in Apc(Delta 716) knockout mice. *Nat Med.* 2001; 7(9):1048–51. [PubMed: 11533709]
107. Mutoh M, et al. Involvement of prostaglandin E receptor subtype EP(4) in colon carcinogenesis. *Cancer Res.* 2002; 62(1):28–32. [PubMed: 11782353]
108. Amano H, et al. Host prostaglandin E(2)-EP3 signaling regulates tumor-associated angiogenesis and tumor growth. *J Exp Med.* 2003; 197(2):221–32. [PubMed: 12538661]
109. Fulton AM, Ma X, Kundu N. Targeting prostaglandin E EP receptors to inhibit metastasis. *Cancer Res.* 2006; 66(20):9794–7. [PubMed: 17047037]
110. Watanabe K, et al. Inhibitory effect of a prostaglandin E receptor subtype EP(1) selective antagonist, ONO-8713, on development of azoxymethane-induced aberrant crypt foci in mice. *Cancer Lett.* 2000; 156(1):57–61. [PubMed: 10840160]
111. Holt D, et al. Prostaglandin E(2) (PGE (2)) suppresses natural killer cell function primarily through the PGE(2) receptor EP4. *Cancer Immunol Immunother.* 2011; 60(11):1577–86. [PubMed: 21681369]
112. Wang D, Dubois RN. Prostaglandins and cancer. *Gut.* 2006; 55(1):115–22. [PubMed: 16118353]
113. Ahmadi M, Emery DC, Morgan DJ. Prevention of both direct and cross-priming of antitumor CD8+ T-cell responses following overproduction of prostaglandin E2 by tumor cells in vivo. *Cancer Res.* 2008; 68(18):7520–9. [PubMed: 18794140]
114. Scandella E, et al. Prostaglandin E2 is a key factor for CCR7 surface expression and migration of monocyte-derived dendritic cells. *Blood.* 2002; 100(4):1354–61. [PubMed: 12149218]
115. Oshima M, et al. Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). *Cell.* 1996; 87(5):803–9. [PubMed: 8945508]
116. Tsujii M, et al. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. *Cell.* 1998; 93:705–716. [PubMed: 9630216]
117. Seno H, et al. Cyclooxygenase 2- and prostaglandin E(2) receptor EP(2)-dependent angiogenesis in Apc(Delta716) mouse intestinal polyps. *Cancer Res.* 2002; 62(2):506–11. [PubMed: 11809702]
118. Kamiyama M, et al. EP2, a receptor for PGE2, regulates tumor angiogenesis through direct effects on endothelial cell motility and survival. *Oncogene.* 2006; 25(53):7019–28. [PubMed: 16732324]
119. Davies G, et al. Cyclooxygenase-2 (COX-2), aromatase and breast cancer: a possible role for COX-2 inhibitors in breast cancer chemoprevention. *Ann Oncol.* 2002; 13(5):669–78. [PubMed: 12075734]
120. Fujiwaki R, et al. Cyclooxygenase-2 expression in endometrial cancer: correlation with microvessel count and expression of vascular endothelial growth factor and thymidine phosphorylase. *Hum Pathol.* 2002; 33(2):213–9. [PubMed: 11957147]
121. Joo YE, et al. Cyclooxygenase-2 overexpression correlates with vascular endothelial growth factor expression and tumor angiogenesis in gastric cancer. *J Clin Gastroenterol.* 2003; 37(1):28–33. [PubMed: 12811205]
122. Zhang J, et al. Cyclooxygenase-2 expression is associated with VEGF-C and lymph node metastases in gastric cancer patients. *Biomed Pharmacother.* 2005; 59(Suppl 2):S285–8. [PubMed: 16507394]
123. Timoshenko AV, et al. COX-2-mediated stimulation of the lymphangiogenic factor VEGF-C in human breast cancer. *Br J Cancer.* 2006; 94(8):1154–63. [PubMed: 16570043]

124. Soumaoro LT, et al. Coexpression of VEGF-C and Cox-2 in human colorectal cancer and its association with lymph node metastasis. *Dis Colon Rectum*. 2006; 49(3):392–8. [PubMed: 16474989]
125. Su JL, et al. Cyclooxygenase-2 induces EP1- and HER-2/Neu-dependent vascular endothelial growth factor-C up-regulation: a novel mechanism of lymphangiogenesis in lung adenocarcinoma. *Cancer Research*. 2004; 64(2):554–564. [PubMed: 14744769]
126. Iwata C, et al. Inhibition of cyclooxygenase-2 suppresses lymph node metastasis via reduction of lymphangiogenesis. *Cancer Res*. 2007; 67(21):10181–9. [PubMed: 17974958]
127. Hosono K, et al. Roles of prostaglandin E2-EP3/EP4 receptor signaling in the enhancement of lymphangiogenesis during fibroblast growth factor-2-induced granulation formation. *Arterioscler Thromb Vasc Biol*. 2011; 31(5):1049–58. [PubMed: 21311040]
128. Chakroborty D, et al. Catecholamines regulate tumor angiogenesis. *Cancer Res*. 2009; 69(9): 3727–30. [PubMed: 19383906]
129. Cole SW, et al. Transcript origin analysis identifies antigen-presenting cells as primary targets of socially regulated gene expression in leukocytes. *Proc Natl Acad Sci U S A*. 2011; 108(7):3080–5. [PubMed: 21300872]
130. Lutgendorf SK, et al. Biobehavioral influences on matrix metalloproteinase expression in ovarian carcinoma. *Clin Cancer Res*. 2008; 14(21):6839–46. [PubMed: 18980978]
131. Moreno-Smith M, et al. Biologic effects of dopamine on tumor vasculature in ovarian carcinoma. *Neoplasia*. 2013; 15(5):502–10. [PubMed: 23633922]
132. Roddie IC, et al. Lymphatic motility. *Lymphology*. 1980; 13(4):166–72. [PubMed: 7009999]
133. McHale NG. Lymphatic innervation. *Blood Vessels*. 1990; 27(2-5):127–36. [PubMed: 1700733]
134. Madden KS, Szpunar MJ, Brown EB. beta-Adrenergic receptors (beta-AR) regulate VEGF and IL-6 production by divergent pathways in high beta-AR-expressing breast cancer cell lines. *Breast Cancer Res Treat*. 2011; 130(3):747–58. [PubMed: 21234673]
135. Landen CN Jr, et al. Neuroendocrine modulation of signal transducer and activator of transcription-3 in ovarian cancer. *Cancer Res*. 2007; 67(21):10389–96. [PubMed: 17974982]
136. Shi M, et al. Catecholamine up-regulates MMP-7 expression by activating AP-1 and STAT3 in gastric cancer. *Mol Cancer*. 2010; 9:269. [PubMed: 20939893]
137. Yang EV, et al. Norepinephrine up-regulates the expression of vascular endothelial growth factor, matrix metalloproteinase (MMP)-2, and MMP-9 in nasopharyngeal carcinoma tumor cells. *Cancer Res*. 2006; 66(21):10357–64. [PubMed: 17079456]
138. Sood AK, et al. Adrenergic modulation of focal adhesion kinase protects human ovarian cancer cells from anoikis. *J Clin Invest*. 2010; 120(5):1515–23. [PubMed: 20389021]
139. Sastry KS, et al. Epinephrine protects cancer cells from apoptosis via activation of cAMP-dependent protein kinase and BAD phosphorylation. *J Biol Chem*. 2007; 282(19):14094–100. [PubMed: 17353197]
140. Halford MM, Tebbutt NC, Desai J, Achen M.G. and Stacker, S.A. Towards the biomarker-guided rational use of anti-angiogenic agents in the treatment of metastatic colorectal cancer. *Colorectal Cancer*. 2012; 1(2):149–161.
141. Ferrara N, et al. Targeting VEGF-A to treat cancer and age-related macular degeneration. *Annu.Rev.Med*. 2007; 58:491–504. [PubMed: 17052163]
142. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. *Science*. 2005; 307(5706):58–62. [PubMed: 15637262]
143. Ciombor KK, Berlin J, Chan E. Aflibercept. *Clin. Cancer Res*. 2013; 19(8):1920–5. [PubMed: 23444216]
144. Chung AS, et al. An interleukin-17-mediated paracrine network promotes tumor resistance to anti-angiogenic therapy. *Nature Med*. 2013
145. Davydova N, et al. The VD1 neutralizing antibody to vascular endothelial growth factor-D: binding epitope and relationship to receptor binding. *J. Mol. Biol*. 2011; 407(4):581–93. [PubMed: 21315726]

146. Persaud K, et al. Involvement of the VEGF receptor 3 in tubular morphogenesis demonstrated with a human anti-human VEGFR-3 monoclonal antibody that antagonizes receptor activation by VEGF-C. *J. Cell Science*. 2004; 117:2745–2756. Pt 13. [PubMed: 15150322]
147. Caunt M, et al. Blocking neuropilin-2 function inhibits tumor cell metastasis. *Cancer Cell*. 2008; 13(4):331–42. [PubMed: 18394556]
148. He Y, et al. Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling. *J. Natl. Cancer Inst*. 2002; 94(11):819–825. [PubMed: 12048269]
149. Holopainen T, et al. Effects of angiopoietin-2-blocking antibody on endothelial cell-cell junctions and lung metastasis. *J Natl Cancer Inst*. 2012; 104(6):461–75. [PubMed: 22343031]
150. Procopio G, et al. Experience with sorafenib in the treatment of advanced renal cell carcinoma. *Ther. Adv. Urol*. 2012; 4(6):303–13. [PubMed: 23205057]
151. Verweij J, Sleijfer S. Pazopanib, a new therapy for metastatic soft tissue sarcoma. *Expert. Opin. Pharmacother*. 2013; 14(7):929–35. [PubMed: 23488774]
152. Mankal P, O'Reilly E. Sunitinib malate for the treatment of pancreas malignancies--where does it fit? *Expert. Opin. Pharmacother*. 2013; 14(6):783–92. [PubMed: 23458511]
153. Grunwald V, Merseburger AS. Axitinib for the treatment of patients with advanced metastatic renal cell carcinoma (mRCC) after failure of prior systemic treatment. *Onco. Targets. Ther*. 2012; 5:111–7. [PubMed: 22787405]
154. Davis SL, et al. The development of regorafenib and its current and potential future role in cancer therapy. *Drugs Today (Barc)*. 2013; 49(2):105–15. [PubMed: 23462625]
155. Ulrich CM, Bigler J, Potter JD. Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics. *Nat Rev Cancer*. 2006; 6(2):130–40. [PubMed: 16491072]
156. DuBois RN. Nonsteroidal anti-inflammatory drug use and sporadic colorectal adenomas. *Gastroenterology*. 1995; 108(4):1310–4. [PubMed: 7698600]
157. Thun MJ, Henley SJ, Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. *J Natl Cancer Inst*. 2002; 94(4):252–66. [PubMed: 11854387]
158. Rothwell PM, et al. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. *Lancet*. 2012
159. Rothwell PM, et al. Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. *Lancet*. 2012; 379:1591–1601. [PubMed: 22440947]
160. Kune GA, Kune S, Watson LF. Colorectal cancer risk, chronic illnesses, operations, and medications: case control results from the Melbourne Colorectal Cancer Study. *Cancer Res*. 1988; 48(15):4399–404. [PubMed: 3390835]
161. Thun MJ, Jacobs EJ, Patrono C. The role of aspirin in cancer prevention. *Nat Rev Clin Oncol*. 2012
162. Rothwell PM, et al. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. *Lancet*. 2011; 377(9759):31–41. [PubMed: 21144578]
163. Leitzmann MF, et al. Aspirin use in relation to risk of prostate cancer. *Cancer Epidemiol. Biomarkers Prev*. 2002; 11:1108–11. 10 Pt 1. [PubMed: 12376516]
164. Brasky TM, et al. Non-steroidal anti-inflammatory drug (NSAID) use and breast cancer risk in the Western New York Exposures and Breast Cancer (WEB) Study. *Cancer Causes Control*. 2010; 21(9):1503–12. [PubMed: 20499154]
165. Hirsch HA, et al. A transcriptional signature and common gene networks link cancer with lipid metabolism and diverse human diseases. *Cancer Cell*. 2010; 17(4):348–61. [PubMed: 20385360]
166. Holmes MD, et al. Aspirin intake and survival after breast cancer. *J. Clin. Oncol*. 2010; 28(9):1467–72. [PubMed: 20159825]
167. von Rahden BH, et al. Coexpression of cyclooxygenases (COX-1, COX-2) and vascular endothelial growth factors (VEGF-A, VEGF-C) in esophageal adenocarcinoma. *Cancer Res*. 2005; 65(12):5038–5044. [PubMed: 15958546]

168. Guo GL, et al. The effect of cyclooxygenase-2 on lymphangiogenesis in breast cancer. *Zhonghua Wai Ke Za Zhi*. 2008; 46(2):132–5. [PubMed: 18509974]
169. Kubo H, et al. Spontaneous regression of recurrent and metastatic Merkel cell carcinoma. *J Dermatol*. 2007; 34(11):773–7. [PubMed: 17973819]
170. Liu H, et al. Inhibition of cyclooxygenase-2 suppresses lymph node metastasis via VEGF-C. *Anat Rec (Hoboken)*. 2009; 292(10):1577–83. [PubMed: 19685508]
171. Black JW, et al. A New Adrenergic Betareceptor Antagonist. *Lancet*. 1964; 1(7342):1080–1. [PubMed: 14132613]
172. Lee JW, et al. Surgical stress promotes tumor growth in ovarian carcinoma. *Clin Cancer Res*. 2009; 15(8):2695–702. [PubMed: 19351748]
173. Benjamin B, et al. Effect of beta blocker combined with COX-2 inhibitor on colonic anastomosis in rats. *Int J Colorectal Dis*. 2010; 25(12):1459–64. [PubMed: 20556396]
174. Melhem-Bertrandt A, et al. Beta-Blocker Use Is Associated With Improved Relapse-Free Survival in Patients With Triple-Negative Breast Cancer. *J Clin Oncol*. 2011; 29(19):2645–52. [PubMed: 21632501]
175. Botteri E, et al. Therapeutic effect of beta-blockers in triple-negative breast cancer postmenopausal women. *Breast Cancer Res Treat*. 2013; 140(3):567–75. [PubMed: 23912960]
176. Ganz PA, et al. Examining the influence of beta blockers and ACE inhibitors on the risk for breast cancer recurrence: results from the LACE cohort. *Breast Cancer Res Treat*. 2011; 129(2):549–56. [PubMed: 21479924]
177. Sorensen GV, et al. Use of beta-blockers, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and risk of breast cancer recurrence: a Danish nationwide prospective cohort study. *J Clin Oncol*. 2013; 31(18):2265–72. [PubMed: 23650417]
178. Powe DG, et al. Beta-blocker drug therapy reduces secondary cancer formation in breast cancer and improves cancer specific survival. *Oncotarget*. 2010; 1(7):628–38. [PubMed: 21317458]
179. Chae YK, et al. Use of ACE Inhibitors and Angiotensin Receptor Blockers and Primary Breast Cancer Outcomes. *J Cancer*. 2013; 4(7):549–56. [PubMed: 23983819]
180. Chae YK, et al. Reduced risk of breast cancer recurrence in patients using ACE inhibitors, ARBs, and/or statins. *Cancer Invest*. 2011; 29(9):585–93. [PubMed: 21936625]
181. Grytli HH, et al. Association Between Use of beta-Blockers and Prostate Cancer-Specific Survival: A Cohort Study of 3561 Prostate Cancer Patients with High-Risk or Metastatic Disease. *Eur Urol*. 2013 doi:pii: S0302-2838(13)00010-9.
182. Grytli HH, et al. Use of beta-blockers is associated with prostate cancer-specific survival in prostate cancer patients on androgen deprivation therapy. *Prostate*. 2013; 73(3):250–60. [PubMed: 22821802]
183. Kerbel RS. Strategies for improving the clinical benefit of antiangiogenic drug based therapies for breast cancer. *J Mammary Gland Biol Neoplasia*. 2012; 17(3-4):229–39. [PubMed: 23011602]
184. Shan T, et al. beta2-adrenoceptor blocker synergizes with gemcitabine to inhibit the proliferation of pancreatic cancer cells via apoptosis induction. *Eur J Pharmacol*. 2011; 665(1-3):1–7. [PubMed: 21570961]
185. Priceman SJ, et al. Targeting distinct tumor-infiltrating myeloid cells by inhibiting CSF-1 receptor: combating tumor evasion of antiangiogenic therapy. *Blood*. 2010; 115(7):1461–71. [PubMed: 20008303]

RESEARCH AND CLINICAL AGENDA

- Beta-blockers and NSAIDS may complement existing anti-angiogenesis strategies to treat cancer.
- Further research is required to define the receptors and signalling pathways that mediate these effects and windows of therapeutic opportunity
- An unbiased evaluation of beta-blockers to treat cancer requires randomized clinical trials in defined patient populations.

Figure 1. Interactions between tumour cells and their microenvironment may be targeted by novel anti-cancer strategies

The stroma associated with a growing tumour consists of immune cell infiltrates, tumour-associated fibroblasts, sympathetic nerve fibres and endothelial cells and pericytes from blood and lymphatic vessels. Information flow in the form of soluble molecular signals and direct cell-cell contact occurs between the malignant tumour cells and the stromal cells. The boxes show examples of drug classes that may be used to manipulate these interactions *in vivo*.

Figure 2. Potential peri-operative application of drugs that target vasculature and neural signalling

Summary of the potential applications of different major drugs classes that target blood vessels, lymphatic vessels and neural signalling for cancer patients prior to surgery, in the peri-operative phase, and after surgery.

TABLE 1

CANCER RELATED OUTCOMES ASSOCIATED WITH BETA-BLOCKER USE

Cancer type	Key outcomes associated with beta-blocker use	Subjects	Cohort	Year	Reference
Breast	Reduced incidence of cancer-related events Reduced distant metastasis Reduced cancer specific mortality	800	European Institute of Oncology, Milan, Italy	1997-2008	Botteri et al. 2013
Breast	No association with cancer-related outcomes	18,733	Danish Breast Cancer Cooperative Group Registry	1996-2003	Sorensen et al. 2013
Breast	No association with cancer-related outcomes	4,661	Nurses' Health Study, USA	1985-2005	Holmes et al. 2013
Breast	No association with cancer-related outcomes	2,763	Cancer Surveillance System, SEER program, NCI, USA	2000-2008	Li et al. 2013
Breast	Increased 3 year relapse-free survival Reduced Lymphovascular Invasion (LVI)	1,413	Breast Cancer Management System, MD Anderson Cancer Center, TX, USA	1995-2007	Melhem-Bertrandt et al. 2011
Breast	No association with cancer-related outcomes	2,269	LACE Study, Kaiser Permanente Northern California subset, USA	2000-2002	Ganz et al. 2011
Breast	Propranolol use was associated with Lower tumour grade at diagnosis Lower stage, reduced metastasis Reduced 5 year cancer-specific mortality Atenolol use was not associated with cancer-related outcomes	5,333	General Medical Services National Cancer Registry, Ireland	2001-2006	Barron et al. 2011
Breast	Increased time to distant metastasis Reduced recurrence and metastasis Reduced cancer specific mortality	466	Nottingham City Hospital, UK	1987-1994	Powe et al. 2010
Breast	No association with cancer risk Progression was not investigated	49,950	Danish Cancer Registry	1989-2002	Fryzek et al. 2006
Breast	No association with cancer risk Progression was not investigated	17,861	General Practice Research Database, London, UK	1992-1997	Meier et al. 2000
Lung (NSCLC)	Increased metastasis-free survival Increased disease-free survival Increased overall survival	722	MD Anderson Cancer Center, TX, USA	1998-2010	Wang et al. 2012
Lung	No association with cancer mortality	8,039	Department of Health Hypertension Care Computing Project, UK	1971-1986	Fletcher et al. 1993
Ovarian	No association with cancer mortality	6,626	Danish Cancer Registry	1999-2010	Johannesdottir et al. 2013
Ovarian	No association with progression-free survival	381	AGO-OVAR clinical trial subset	1997-2002	Heitz et al. 2013
Ovarian	Increased progression-free survival Increased overall survival	248	Gynecologic Oncology Service, Cedars-Sinai Medical Center, CA, USA	1999-2006	Diaz et al. 2012
Melanoma	No association with cancer mortality	709	Eindhoven Cancer Registry, The Netherlands	1998-2010	Livingstone et al. 2013
Melanoma	Reduced disease progression Increased disease-free survival	121	Department of Dermatology, University of Florence, Italy	1993-2009	De Giorgi et al. 2011
Melanoma	Trend toward reduced mortality	4,179	Danish Cancer Registry	1943-2006	Lemeshow et al. 2011

Cancer type	Key outcomes associated with beta-blocker use	Subjects	Cohort	Year	Reference
Prostate	Reduced Prostate Specific Antigen at diagnosis Reduced metastasis Reduced risk of cancer-specific mortality	3,561	Cancer Registry of Norway	2004-2009	Grytli et al. 2013 (Euro Onco)
Prostate	No association with cancer-specific risk or mortality in whole cohort Decreased cancer specific mortality in patients who received androgen deprivation therapy	6,515	Oslo II Study 2000 – Cancer Registry of Norway	1972-2000	Grytli et al. 2013 (The Prostate)
Colorectal	No association with cancer risk Long term (6+ year) use was associated with higher stage	3,470	DACHS study, Odenwald, Germany	2003-2007	Jansen et al. 2012
Multiple	Reduced overall risk of cancer Progression was not investigated	1,340 diabetes patients	Diabetes Clinic, University of Florence, Italy	1998-2007	Monami et al. 2013
Multiple	No association with cancer risk	12877*	Kaiser Permanente Medical Care Program, CA, USA	1994-2008	Friedman et al. 2011
Multiple	Reduced survival from pancreatic or prostate cancer	3,462	DIN-LINK Database, UK	1997-2006	Shah et al. 2011